30742-62-2

Basic information

• Product Name: 2-MORPHOLINO-5-NITROBENZALDEHYDE
• Synonyms: 2-MORPHOLINO-5-NITROBENZALDEHYDE;2-(4-MORPHOLINYL)-5-NITROBENZALDEHYDE;ASISCHEM R39042;2-morpholino-5-nitrobenzenecarbaldehyde;2-(Morpholin-4-yl)-5-nitrobenzaldehyde;4-(2-Formyl-4-nitrophenyl)morpholine;4-(2-Formyl-4-nitrophenyl)morpholine, 3-Formyl-4-(morpholin-4-yl)nitrobenzene
• CAS NO: 30742-62-2
• Molecular Formula: C₁₁H₁₂N₂O₄
• Molecular Weight: 236.22
• Mol File: 30742-62-2.mol
• Article Data: 7

Chemical Properties

• Melting Point: 115 °C
• Boiling Point: 437°C at 760 mmHg
• Flash Point: 218.1°C
• Appearance: /
• Density: 1.34g/cm³
• Vapor Pressure: 7.75E-08mmHg at 25°C
• Refractive Index: 1.613
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 2-MORPHOLINO-5-NITROBENZALDEHYDE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-MORPHOLINO-5-NITROBENZALDEHYDE(30742-62-2)
• EPA Substance Registry System: 2-MORPHOLINO-5-NITROBENZALDEHYDE(30742-62-2)

Safety Data

• Hazard Codes: Xi:Irritant
• Statements: R36/37/38:Irritating to eyes, respiratory system and skin.
• Safety Statements: S26:In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.; S37/39:Wear suitable g
• HazardClass: IRRITANT
• Hazardous Substances Data: 30742-62-2(Hazardous Substances Data)

Usage

General Description

2-morpholino-5-nitrobenzaldehyde is a chemical compound with the molecular formula C10H10N2O4. It is a yellow solid that is commonly used as an intermediate in the synthesis of pharmaceuticals and organic compounds. 2-morpholino-5-nitrobenzaldehyde contains a nitro group and an aldehyde group, making it suitable for reactions such as reduction and condensation. 2-morpholino-5-nitrobenzaldehyde is also used in the production of dyes and pigments due to its aromatic structure and ability to form complex organic molecules. Additionally, it is considered to be toxic and should be handled with care in a controlled laboratory setting.

InChI:InChI=1/C11H12N2O4/c14-8-9-7-10(13(15)16)1-2-11(9)12-3-5-17-6-4-12/h1-2,7-8H,3-6H2

Upstream product

• 110-91-8 morpholine 
• 6361-21-3 2-chloro-5-nitrobenzaldehyde 

Downstream Products

• 30742-77-9 bis-(2-morpholin-4-yl-5-nitro-benzylidene)-hydrazine 
• 30742-68-8 2-morpholin-4-yl-5-nitro-benzaldehyde (toluene-4-sulfonyl)-hydrazone 
• 296244-43-4 1,3-dimethyl-5-(2-morpholino-5-nitrobenzylidene)hexahydropyrimidine-2,4,6-trione 
• 58028-88-9 2-benzoylamino-3-(2-morpholin-4-yl-5-nitro-phenyl)-acrylic acid 
• 58028-94-7 2-benzoylamino-3-(2-morpholin-4-yl-5-nitro-phenyl)-acrylic acid methyl ester 
• 1093798-67-4 C₁₈H₂₇N₃O₅ 
• 959755-61-4 (5-bromo-[1,2,4]triazolo[1,5-a]pyrazin-8-yl)-[3-(tert-butyl-dimethyl-silanyloxymethyl)-4-morpholin-4-yl-phenyl]-amine 
• 959755-64-7 [5-(5-bromo-[1,2,4]triazolo[1,5-a]pyrazin-8-ylamino)-2-morpholin-4-yl-phenyl]-methanol 

Relevant articles and documents

PYRIMIDOPYRIMIDINONES USEFUL AS WEE-1 KINASE INHIBITORS

The present invention relates to compounds that are useful as inhibitors of the activity of Wee-1 kinase. The present invention also relates to pharmaceutical compositions comprising these compounds and to methods of using these compounds in the treatment of cancer and methods of treating cancer.

Discovery of kinase spectrum selective macrocycle (16E)-14-methyl-20-oxa-5, 7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27) ,9,11,16,21,23-decaene (SB1317/TG02), a potent inhibitor of cyclin dependent kinases (CDKs), Janus kinase 2 (JAK2), and Fms-like tyrosine kinase-3 (FLT3) for the treatment of cancer

Herein, we describe the design, synthesis, and SAR of a series of unique small molecule macrocycles that show spectrum selective kinase inhibition of CDKs, JAK2, and FLT3. The most promising leads were assessed in vitro for their inhibition of cancer cell proliferation, solubility, CYP450 inhibition, and microsomal stability. This screening cascade revealed 26h as a preferred compound with target IC50 of 13, 73, and 56 nM for CDK2, JAK2 and FLT3, respectively. Pharmacokinetic (PK) studies of 26h in preclinical species showed good oral exposures. Oral efficacy was observed in colon (HCT-116) and lymphoma (Ramos) xenograft studies, in line with the observed PK/PD correlation. 26h (SB1317/TG02) was progressed into development in 2010 and is currently undergoing phase 1 clinical trials in advanced leukemias and multiple myeloma.

Protecting-group-free amination of halogenated nitrobenzaldehyde with palladium catalyst

"One-step" method for the synthesis of secondary aliphatic amine substituted nitrobenzaldehyde was developed. In the presence of Pd catalyst, halogenated nitrobenzaldehyde could be smoothly coupled with secondary aliphatic amine to give the target product